ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
12 announcements with these filters
Q2 consolidated revenue ₹105.61 Cr (+102%), PAT ₹17.18 Cr (+84%). EBITDA margin recovered to 23.9%, still below the 25-30% guided band. FY27 revenue reiterated at ₹380-400 Cr.
Q2FY27 consolidated revenue ₹105.6 Cr (+102.3% YoY), EBITDA ₹25.2 Cr (+84.1%), PAT ₹17.2 Cr (+84.4%). H1 FY27 revenue ₹193.2 Cr (+125.9%). Strategy: integrated API-to-formulations platform.
Anlon Healthcare Ltd reported revenue from operations of ₹105.6 Cr (+102.3% YoY) and net profit of ₹17.2 Cr (+84.9% YoY) for Q2 FY27.
Anlon Healthcare received NSE and BSE in-principle approval for 8,05,35,651 preferential shares under a share swap. No cash consideration is stated.
Anlon Healthcare will hold a board meeting on 29 October 2026 to consider unaudited standalone and consolidated half-yearly results. The trading window is closed from 1 October to 31 October 2026.
Anlon Healthcare Limited filed the mandatory Regulation 74(5) certificate from its Registrar and Share Transfer Agent for the quarter ended September 30, 2026.
Anlon Healthcare approved a preferential issue of convertible warrants for up to Rs. 250 Crore to raise funds for the company.
Anlon Healthcare Ltd scheduled a board meeting for October 13, 2026, to deliberate on business expansion plans and potential fund-raising.
Anlon Healthcare incorporated ANLON Healthcare Nigeria Limited, holding 90% stake. The subsidiary aims to expand pharmaceutical and healthcare operations across 16 West African countries.
Anlon Healthcare's AGM approved acquiring Apiqo Organics and Bizotic Lifescience stakes via share swap. The filing adds preferential issue pricing of ₹17.85 per share.
Anlon Healthcare responded to NSE/BSE surveillance queries stating no undisclosed information explains the price movement. The company attributes the move to market-driven factors.
Brickwork Ratings assigned BWR BBB/Stable to Anlon Healthcare's ₹23.60 Crore fund-based term loan. The rating reflects improved profitability and low leverage following the company's 2025 IPO.